Daily Exendin Insights Optimize Your Intraperitoneal Health Today

Overview of Daily Intraperitoneal Exendin

Female NOD mice with new onset diabetes received either Ex-4 (0.2 μg) or saline via daily intraperitoneal injection for 30 days. To maintain viability after diagnosis of diabetes, animals also received subcutaneous insulin pellets. When persistent hyperglycemia returned, animals were sacrificed and histological studies performed to assess beta-cell proliferation (BrdU+/insulin+; Ki67 ...

Mice in the Exendin-4 treatment group receive intraperitoneal injections of 25 nmol/kg Exendin-4 daily for 10 days, then three times per week for the duration of the study.

Key Details About Daily Intraperitoneal Exendin

Research design and methods: Female NOD mice with new onset diabetes received either Ex-4 (0.2 microg) or saline via daily intraperitoneal injection for 30 days. To maintain viability after diagnosis of diabetes, animals also received subcutaneous insulin pellets. When persistent hyperglycemia returned, animals were sacrificed and histological studies performed to assess beta-cell ...

Here we show that daily intraperitoneal injection of exendin (1-30) (1 nmol/kg) for 20 d followed by 31 d twice daily to Lepr db /Lepr db (db/db) mice significantly reduced the amount of visceral fat relative to saline-treated controls and improved HbA 1C (control 9.5±0.2% vs treated 7.9±0.2%, p =0.001) but was not as effective as exendin-4.

Useful Notes on Daily Intraperitoneal Exendin

Intraperitoneal injection of exendin-4 (Sigma-Aldrich, St. Louis, MO, USA) was performed 2 weeks after tamoxifen injection. Exendin-4 (0.1 μg/mg of body weight) was administered twice daily ...

After intraperitoneal injection in rats, Exendin-4 has a half-life of 125-174 minutes[8]. The pharmacokinetic profile of the antagonist fragment Exendin-4 (3-39) may differ, and the timing of its administration relative to an agonist challenge should be optimized in pilot studies.

Leptin and leptin resistance in obesity

Daily intraperitoneal injections of recombinant leptin (OB protein) have been shown to reduce body weight, fat mass, food intake, and serum glucose and insulin, while enhancing energy expenditure, body temperature, and physical activity (2, 11).

Glucagon-like peptide-1 is the main hormonal mediator of the enteroinsular axis. Recently, it has additionally received considerable attention as a possible new treatment for Type II (non-insulin-dependent) diabetes mellitus. Its major disadvantage is that its duration of action is too short to achieve good 24-h metabolic control. Exendin-4, which is produced in the salivary glands of Gila ...

PDF Exendin

Introduction Exendin-4, a potent glucagon-like peptide-1 (GLP-1) receptor agonist, is a valuable tool in preclinical research, particularly in mouse models of metabolic disorders and neurodegenerative diseases. Its ability to stimulate glucose-dependent insulin secretion, suppress glucagon release, and exert neuroprotective effects makes it a molecule of significant interest. These application ...

Intraperitoneal (IP) route of drug administration in laboratory animals is a common practice in many in vivo studies of disease models. While this route is an easy to master, quick, suitable for chronic treatments and with low impact of stress on ...